These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32534221)

  • 1. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
    Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
    Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
    Anastasilakis AD; Polyzos SA; Yavropoulou MP; Appelman-Dijkstra NM; Ntenti C; Mandanas S; Papatheodorou A; Makras P
    Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.
    Makras P; Appelman-Dijkstra NM; Papapoulos SE; van Wissen S; Winter EM; Polyzos SA; Yavropoulou MP; Anastasilakis AD
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4155-e4162. PubMed ID: 33978745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.
    Anastasilakis AD; Makras P; Polyzos SA; Papapoulos SE
    Calcif Tissue Int; 2023 Oct; 113(4):469-473. PubMed ID: 37535102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Mass Gains After One Denosumab Injection Followed by Zoledronate.
    Everts-Graber J; Lehmann T
    J Clin Densitom; 2022; 25(3):293-298. PubMed ID: 35450795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
    Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
    J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
    Anastasilakis AD; Polyzos SA; Makras P; Trovas G; Yavropoulou MP; Tournis S
    J Clin Densitom; 2021; 24(4):591-596. PubMed ID: 33541775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting.
    Everts-Graber J; Reichenbach S; Gahl B; Häuselmann H; Ziswiler HR; Studer U; Lehmann T
    Bone; 2022 Oct; 163():116498. PubMed ID: 35882310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Loss After Denosumab: Only Partial Protection with Zoledronate.
    Reid IR; Horne AM; Mihov B; Gamble GD
    Calcif Tissue Int; 2017 Oct; 101(4):371-374. PubMed ID: 28500448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
    Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
    Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
    Khan AA; AbuAlrob H; M'Hiri I; Ali DS; Dandurand K; Said H; Alkassem H; Hakami Y; Hweija I; Iqbal S; Romanovschi M; Mehmood S; Zariffeh H; Guyatt G; Ibrahim Q; Brignardello-Petersen R; Syed HI
    Endocrine; 2023 Jun; 80(3):647-657. PubMed ID: 37186270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
    Horne AM; Mihov B; Reid IR
    Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
    Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
    Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2020 Oct; 35(10):1858-1870. PubMed ID: 32459005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.